Literature DB >> 7481206

Age-adjusted survival curves with application in the Framingham Study.

L A Cupples1, D R Gagnon, R Ramaswamy, R B D'Agostino.   

Abstract

Kaplan-Meier curves provide descriptors of survival information for different subgroups within a data set. Investigators frequently use these figures for descriptive comparison of the effect of a particular measure upon survival. When subjects enter a study at different ages and age is associated with survival, it is often desirable to adjust survival information for age differences in the subgroups. This report discusses several methods for age-adjustment of survival curves, including direct age-adjustment and proportional hazard modelling with age as a covariate.

Mesh：

Year:  1995        PMID： 7481206     DOI： 10.1002/sim.4780141603

Source DB:  PubMed          Journal:  Stat Med        ISSN： 0277-6715            Impact factor:   2.373


  13 in total

1.  A prospective assessment of mortality in chronic spinal cord injury.

Authors:  E Garshick; A Kelley; S A Cohen; A Garrison; C G Tun; D Gagnon; R Brown
Journal:  Spinal Cord       Date:  2005-07       Impact factor: 2.772

2.  Multiple comparisons for survival data with propensity score adjustment.

Authors:  Hong Zhu; Bo Lu
Journal:  Comput Stat Data Anal       Date:  2015-06-01       Impact factor: 1.681

3.  Lower Lean Mass Measured by Dual-Energy X-ray Absorptiometry (DXA) is Not Associated with Increased Risk of Hip Fracture in Women: The Framingham Osteoporosis Study.

Authors:  Robert R McLean; Douglas P Kiel; Sarah D Berry; Kerry E Broe; Xiaochun Zhang; L Adrienne Cupples; Marian T Hannan
Journal:  Calcif Tissue Int       Date:  2018-01-05       Impact factor: 4.333

4.  Adjusting and comparing survival curves by means of an additive risk model.

Authors:  P H Zahl; O O Aalen
Journal:  Lifetime Data Anal       Date:  1998       Impact factor: 1.588

5.  Duration of the anti-androgen in men undergoing 6 months of an LHRH agonist and radiation therapy for unfavorable-risk prostate cancer and the risk of death.

Authors:  N N Sanford; M-H Chen; M Loffredo; A Renshaw; P W Kantoff; A V D'Amico
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-11-08       Impact factor: 5.554

6.  Prostate-Specific Antigen Failure and Risk of Death Within Comorbidity Subgroups Among Men With Unfavorable-Risk Prostate Cancer Treated in a Randomized Trial.

Authors:  Nicholas J Giacalone; Jing Wu; Ming-Hui Chen; Andrew Renshaw; Marian Loffredo; Philip W Kantoff; Anthony V D'Amico
Journal:  J Clin Oncol       Date:  2016-11-01       Impact factor: 44.544

7.  The impact of comorbidity and PSA doubling time on the risk of death in men experiencing PSA failure following radiation therapy with or with androgen deprivation therapy for unfavorable-risk prostate cancer.

Authors:  S A Patel; M-H Chen; M Loffredo; A Renshaw; P W Kantoff; A V D'Amico
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-01-24       Impact factor: 5.554

8.  Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality.

Authors:  Derya Tilki; Ming-Hui Chen; Jing Wu; Hartwig Huland; Markus Graefen; Michelle Braccioforte; Brian J Moran; Anthony V D'Amico
Journal:  JAMA Oncol       Date:  2019-02-01       Impact factor: 31.777

9.  Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  Trevor J Royce; Ming-Hui Chen; Jing Wu; Marian Loffredo; Andrew A Renshaw; Philip W Kantoff; Anthony V D'Amico
Journal:  JAMA Oncol       Date:  2017-05-01       Impact factor: 31.777

10.  Prior-cancer diagnosis in men with nonmetastatic prostate cancer and the risk of prostate-cancer-specific and all-cause mortality.

Authors:  Kristina Mirabeau-Beale; Ming-Hui Chen; Anthony V D'Amico
Journal:  ISRN Oncol       Date:  2014-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.